SCHEMBL15637693

SCHEMBL15637693

O=C(O)c1ccnc(CNCCCN2CCCC2)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM2B Q8NHM5 2/20 0.51
▸ KDM5C P41229 4/20 0.49
▸ KDM4C Q9H3R0 1/20 0.49
▸ SMYD2 Q9NRG4 2/20 0.46
▸ KDM5B Q9UGL1 8/20 0.45
▸ KDM4A O75164 3/20 0.45
▸ KDM5A P29375 3/20 0.45
▸ KDM6B O15054 1/20 0.45
▸ HDAC1 Q13547 1/20 0.43
▸ KDM4B O94953 1/20 0.43
▸ HRH3 Q9Y5N1 2/20 0.41
▸ KDM4D Q6B0I6 1/20 0.40
▸ EHMT2 Q96KQ7 1/20 0.40
▸ EHMT1 Q9H9B1 1/20 0.40
▸ MET P08581 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15636566 0.98 KDM2B (0.49) KDM2BKDM5CKDM4CSMYD2KDM5B
SCHEMBL16291811 0.92 KDM5C (0.51) KDM2BKDM5CKDM4CSMYD2KDM5B
SCHEMBL15636986 0.87 SMYD2 (0.46) KDM5CKDM4CSMYD2KDM5BKDM5A
SCHEMBL16291580 0.83 CCR3 (0.55) —
SCHEMBL18708137 0.82 HRH3 (0.42) SMYD2HRH3EHMT2EHMT1
SCHEMBL15994294 0.80 CYP3A4 (0.43) SMYD2HRH3
SCHEMBL17772490 0.79 KDM5B (0.50) KDM2BKDM5CKDM4CKDM5BKDM4A
SCHEMBL15636768 0.79 SMN1; SMN2 (0.53) KDM2BKDM5CKDM5BKDM4AKDM5A
SCHEMBL15636442 0.78 KDM5B (0.52) KDM2BKDM5CKDM4CKDM5BKDM4A
SCHEMBL2305288 0.77 KDM4C (0.76) KDM2BKDM5CKDM4CKDM5BKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10221139-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-03-05 — — US disclosed
US-10221139-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-03-05 — — US disclosed
US-10189787-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-01-29 — — US disclosed
US-10189787-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-01-29 — — US disclosed
EP-3023415-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2017-12-06 — — EP disclosed
EP-3023415-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2017-12-06 — — EP disclosed
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2017-11-09 — — US disclosed
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2017-11-09 — — US disclosed
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2017-11-09 — — US disclosed
EP-3150582-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. (US) 2017-04-05 — — EP disclosed
EP-3023415-A1 INHIBITORS OF HISTONE DEMETHYLASES Epitherapeutics ApS (DK) 2016-05-25 — — EP disclosed
EP-3023415-A1 INHIBITORS OF HISTONE DEMETHYLASES Epitherapeutics ApS (DK) 2016-05-25 — — EP disclosed
EP-2903968-A1 INHIBITORS OF HISTONE DEMETHYLASES Epitherapeutics ApS (DK) 2015-08-12 — — EP disclosed
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2015-07-23 — — US disclosed
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2015-07-23 — — US disclosed
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2015-07-23 — — US disclosed
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2014-12-18 — — US disclosed
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2014-12-18 — — US disclosed
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2014-12-18 — — US disclosed
WO-2014053491-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS APS (DK) 2014-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10189787-B2 Inhibitors of histone demethylases EHMT1, KDM1B, EHMT2 KDM2B 46/4885KDM5C 31/4885KDM4C 56/4885
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES EHMT1, KDM1B, EHMT2 KDM2B 46/4885KDM5C 31/4885KDM4C 56/4885
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES EHMT1, KDM1B, EHMT2 KDM2B 46/4885KDM5C 31/4885KDM4C 56/4885
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES EHMT1, KDM1B, EHMT2 KDM2B 46/4885KDM5C 31/4885KDM4C 56/4885
US-10221139-B2 Inhibitors of histone demethylases EHMT1, KDM1B, EHMT2 KDM2B 46/4885KDM5C 31/4885KDM4C 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback